

51-102F3 Material Change Report [F]

Item 1 Name and Address of Company

Worldwide Marijuana Inc.
14th Floor, 1040 West Georgia Street
Vancouver, BC V6E 4H8

Item 2 Date of Material Change

October 18, 2017

Item 3 News Release

The news release dated October 18, 2017 was disseminated through Canada Stockwatch and Market News under section 7.1 of National Instrument 51-102.

Item 4 Summary of Material Change

Please refer to attached news release.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

Please refer to attached news release.

5.2 Disclosure for Restructuring Transactions

N/A

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

N/A

Item 8 Executive Officer

Robert van Santen, Chief Executive Officer

Item 9 Date of Report

October 20, 2017

ENDOCAN SOLUTIONS ANNOUNCES MANAGEMENT CHANGES

Vancouver, B.C., October 18, 2017 – Endocan Solutions Inc. (CSE: WWM-Delisted) (the “Company” or “Endocan”) is pleased to announce that Mr. Chris L. MacPherson is joining the Company as Chief Financial Officer. Chris spent 25 years at CIBC Wood Gundy as Vice President & Portfolio Manager, and has extensive experience in the capital markets, as well as a C-Suite executive in the private and public venture capital space.

Chris will be responsible for finance and marketing activities, funding and acquisition opportunities as well as assist in strategic and tactical matters. Chris has sat on several boards, including BC Hydro, and has been active on the political stage. He has also been involved in a number of charities, including Children’s Miracle and Nepal House Society. Ms. Annie Storey has stepped down as CFO but remains as a Company director.
About Endocan Solutions Inc.

Endocan Solutions Inc. is a Reporting Issuer undergoing recapitalization and reorganization. It was delisted from the CSE on December 6, 2016, subsequently put under new management, and recently underwent a name change and share consolidation. The immediate objective is to bring the Company’s filings up to date under National Instrument 51-102, which includes audited annual financial statements, quarterlies, MD&As and Officer Certificates for the years ended October 31, 2015, 2016 and 2017. Following completion of these filings, the Company intends to seek and secure a suitable business acquisition and requalify to meet the listing requirements of the Exchange as a Life Sciences Issuer.

ON BEHALF OF ENDOCAN SOLUTIONS INC.

(signed) “Robert van Santen”
Chief Executive Officer

For further information, please contact:

Greg Patchell
Telephone: +1.250.860.8634

Cautionary statements

This press release contains forward-looking information based on current expectations. Statements about the Company’s expectations are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Endocan Solutions assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor.